Hereditary/Acquired Bleeding Disorders

The goal of this retrospective analysis of the IBM Health MarketScan® database (2008-2018) was to estimate the incremental economic burden of major surgeries in patients with von Willebrand disease (VWD). Patients with VWD were significantly more likely to have had an inpatient admission (odds ratio [OR] = 1.71; 95% CI, 1.52-1.92) or emergency department (ED) visit (OR = 1.41; 95% CI, 1.25-1.59) than those without VWD (P <.0001). The numbers of per-patient inpatient admissions (incidence rate ratio [IRR] = 1.47; 95% CI, 1.35-1.60), ED visits (IRR = 1.44; 95% CI, 1.31-1.59), and outpatient visits (IRR = 1.16; 95% CI 1.11-1.21 ) were significantly greater for patients with VWD vs without VWD (P < .0001). Patients with VWD incurred significantly higher total healthcare costs (medical plus pharmacy coast) per patient than those without VWD ($50,733.89 vs $30,154.84, respectively) (P <.0001). In conclusion, the authors wrote, "Healthcare resource utilization and associated costs among patients undergoing major surgeries were significantly higher for those with VWD than for patients without VWD."